Introduction {#Sec1}
============

The definition of "probiotics" has been adopted by the International Scientific Association and the World Health Organization: "Live microorganisms, if administered in adequate amounts, confer a health benefit on the host" \[[@CR1]\]. Recently, a lot of studies focused on the effect of the probiotic for oral health. Among previous human clinical studies, *Lactobacillus rhamnosus* GG, ATCC 53103 (LGG) and *L. rhamnosus* LC 705 \[[@CR2]\], *Lactobacillus reuteri* \[[@CR3]--[@CR6]\], and *Bifidobacterium* \[[@CR7], [@CR8]\] could inhibit the oral cariogenic bacteria such as *Streptococcus mutans*. LGG and *L. rhamnosus* LC 705 could reduce the prevalence of yeast counts in elder persons \[[@CR9]\]. *Lactobacillus salivarius* TI 2711 could reduce *Porphyromonas gingivalis* counts \[[@CR10]\]. *L. reuteri* could reduce gingivitis and plaque scores \[[@CR11]\]. *Weissella confusa* CMU \[[@CR12]\] and *Streptococcus salivarius* K12 \[[@CR13]\] could reduce halitosis in human study.

*Lactobacillus paracasei* isolated from healthy humans showed antibacterial and anticandidal activities against oral pathogens such as *S. mutans*, *S. salivarius*, *Streptococcus sanguis*, *Staphylococcus aureus*, *Actinomyces viscosus*, *P. gingivalis*, *Candida albican*, *Candida tropicalis*, and *Candida grabata* \[[@CR14]\]. The strongest antimicrobial activity was attributed to *L. paracasei*, *Lactobacillus plantarum*, *L. rhamnosus*, and *L. salivarius* isolated from the persons who had chronic periodontitis or health periodontium \[[@CR15]\]. Lactobacilli isolated from the caries-free instead of caries-prone subjects had a significantly superior capacity to suppress the growth of *S. mutans*; *L. paracasei* was one of the *Lactobacillus* species with the maximum interference activity against *S. mutans* in vitro \[[@CR16]\].

According to these findings, a new product containing probiotics *L. paracasei* aimed to reduce *S. mutans* was designed. However, its ability for reduction of cariogenic pathogens in human is unclear. A randomized human study to evaluate the efficacy of this probiotic *L. paracasei* for dental health is necessary.

The purpose of this study was to evaluate the efficacy of the probiotic *L. paracasei* GMNL-33 for reducing caries-associated salivary microbial counts in healthy adults. *S. mutans* was determined to play a major role in the initiation of caries lesions. Certain *Lactobacillus* species were believed to have a part in the caries progression. The salivary buffer capacity value would also be detected as supplement indicator. The change of the counts of these two microbials and the salivary buffer capacity has been utilized in documented investigations for caries risk evaluation. Thus, the two indicators would be deemed adequate to assess the efficacy of the *L. paracasei* for caries prevention. The null hypothesis was that the probiotic *L. paracasei* GMNL-33 would not alter the bacterial levels and salivary buffer capacity compared with placebo controls.

Materials and methods {#Sec2}
=====================

The study protocol was approved by the Institutional Reviewing Broad (IRB 96-0311B) and Chang Gung Medical Research Project (XMRPG 460021) at Human Investigation Committee of Chang Gung Memorial Hospital and Chang Gung University. Informed consent from each subject was obtained prior to the clinical trial.

Participants {#Sec3}
------------

Eighty healthy volunteer subjects, aged 20--40 years, were recruited for the study. Grouping by randomized, double-blind method, there were 42 and 38 samples for the probiotic and control group, respectively, at the beginning of study. The inclusion criteria were healthy adults without any prescribed medication. The exclusion criteria were persons with smoking, systemic disease, long-term use of antibiotics, or undergoing dental treatment including orthodontic, periodontal, endodontic, and prosthodontic treatment.

Study protocol and the intervention {#Sec4}
-----------------------------------

The study was a randomized, double-blind, placebo-controlled study with two parallel groups. The oral tablets for the probiotic group and control group were randomized, numbered from first to ninth according to a computer-generated blocked, randomization list. For blinding purposes, the packaging of both oral tablets was identical. A total of 80 participants were randomized to receive one package of oral tablets. The probiotic oral tablets, commercial name as Dental-Lac, contained 11% xylitol and 4% exact of *L. paracasei* GMNL-33 bacteria 3 × 10^8^ cells/tablet (1 g). The control tablets contained 11% xylitol without probiotic strain. All of these oral tablets were prepared by GenMont Biotech Incorporation, Taiwan. Subjects were instructed to take one oral tablet and dissolve it in the mouth slowly after meals three times a day for 2 weeks. Throughout the study, they were supposed to turn in a diary about how often they had taken the oral tablets.

The study consisted of two 2-week periods: a 2-week intervention period (T1--T2) and a 2-week posttreatment period (T2--T3). Bacterial counts of salivary *S. mutans*, lactobacilli, and salivary buffer capacity were evaluated with chair-side kits at baseline (T1), at the completion (T2) of medication and 2 weeks after medication (T3).

The subjects could use toothbrushes, fluoride toothpaste, and dental floss during the study period. The use of other fluoride products, similar probiotic products, and other medical oral rinse was forbidden. The participants were told to brush their teeth twice a day.

Clinical examination {#Sec5}
--------------------

The subjects received an oral examination before the study by two experienced dentists. The clinical examination was conducted by using the oral mirror and Community Periodontal Index probe under the natural light and according to the WHO criteria (World Health Organization, *Oral Health Surveys Basic Method 4th ed.*). The number of decayed/missing/filled teeth (DMFT) was recorded.

Saliva samples {#Sec6}
--------------

Salivary microbials were collected three times at week 0, 2, and 4 around noon time (11:00 a.m.--1:00 p.m.). The subjects were told to refrain from eating and drinking for 2 h prior to the investigation.

Salivary counts of *S. mutans* were determined by using the Dentocult SM Strip mutans® slides (Orion Diagnostica, Finland). One of the examiners placed a bacitracin tablet in the selective culture broth about 15 min before examination. Subjects chewed on a paraffin pellet for 1 min and were instructed to swallow any excess saliva. They then pressed the rough surface of the strip against the saliva remaining on the tongue. The strip that immersed with saliva was placed in the selective culture broth. We incubated the vial in an upright position at 37°C for 48 h with the cap one quarter of a turn open. After incubation, the presence of *S. mutans* was evidenced by dark blue to light blue, raised colonies on the rough surface of the strip. The density of *S. mutans* was obtained by comparing the colony density on the test strip with the model chart: score = 0 for density less than or equal to 10^4^ CFU/ml, score = 1 for density between 10^4^ and 10^5^ CFU/ml, score = 2 for density between 10^5^ and 10^6^ CFU/ml, and score = 3 for density greater than 10^6^ CFU/ml.

Salivary counts of lactobacilli were determined by using the Dentocult LB Dip Slide® method (Orion Diagnostica, Finland). We let the subjects chew on a paraffin pellet for 2 min and collected the stimulated saliva. Some drops of stimulated saliva were pipetted on to both surfaces of the agar dip slides. We incubated the vial in an upright position at 37°C for 4 days. The results were presented as: score = 0 for density equal to 10^3^ CFU/ml, score = 1 for density equal to 10^4^ CFU/ml, score = 2 for density equal to 10^5^ CFU/ml, and score = 3 for density equal to 10^6^ CFU/ml.

There were three clinicians evaluating the test kits. The agreement of the final measurement values of *S. mutans* and lactobacilli with three clinicians was 0.79 to 0.88 and 0.69 to 0.85, respectively. The validity of these methods has found to be good \[[@CR17]\].

Salivary buffering capacity was determined by using the Dentobuff® Strip method (Orion Diagnostica, Finland). A drop of stimulated saliva was pipetted onto the pad, and the result was read after 5 min. The color of this test pad was compared with a standard color chart after 5 min to estimate the final pH. The method grades stimulated saliva as low (pH ≤4), intermediate (pH 4.5--5.5), or high (pH ≥6) buffer capacity. The results were presented as: score = 0 for low pH, score = 1 for intermediate pH, and score = 2 for high pH.

Statistical analysis {#Sec7}
--------------------

Inter-group differences in salivary *S. mutans* counts, salivary lactobacilli counts, and buffer capacity were analyzed by Mann--Whitney *U* Test. Intra-group differences in three stages of salivary *S. mutans* counts, salivary lactobacilli counts, and salivary buffer capacity were analyzed by the Wilcoxon signed-rank test. Fisher's exact test was applied to test the percentage of change in salivary *S. mutans* counts, salivary lactobacilli counts, and salivary buffer capacity. All the analyses were performed via Statistical Package for Social Sciences (SPSS version 12.1 Inc., Chicago, IL, USA) software. The level of statistical significance was set at *p* = 0.05.

Results {#Sec8}
=======

There were 80 adult volunteers involved the clinical trial and the number of investigated subjects were given in the flow chart (Fig. [1](#Fig1){ref-type="fig"}). Two participants of the control group dropped out during the study period. There were 42 subjects (21 female and 21 male, average age 21.0 ± 1.2 years old, DMFT 7.2 ± 5.2) in the probiotic group and 36 subjects (21 female and 17 males, average age 21.1 ± 2.1 years old, DMFT 5.4 ± 3.4) in the control group. The DMFT values between the two groups were analyzed by Mann--Whitney *U* test. There were no significant differences in the DMFT values between the two groups (*p* = 0.218). Fig. 1Flow chart showing the number of subjects in test and control groups at the commencement and completion of the study

The compliance of subjects was reported by themselves through a record chart for oral tablets intake frequency. The compliance results were presented as: "excellent" for eating all tablets, "good" for only missing 1∼5 tablets, "moderate" for missing 6∼10 tablets, and "poor" for missing more than 10 tablets. The excellent compliance was 41.33%, good was 40.00%, moderate was 12.00%, and poor was 6.67%.

The comparison results of *S. mutans* counts, lactobacilli counts, and buffer capacity were not significant between probiotic and control groups at T1, T2, and T3. The data was analyzed by Mann--Whitney *U* test. (Table [1](#Tab1){ref-type="table"}) Table 1The median of *Streptococcus mutans* counts, lactobacilli counts, and buffer capacityIndexTimeProbiotic group median (range)Control group median (range)*p* value^a^*Streptococcus mutans* countsT12 (0 ∼ 3)1.5 (0 ∼ 3)0.904T22 (0 ∼ 3)2 (0 ∼ 3)0.875T31 (0 ∼ 3)2 (0 ∼ 3)0.219*p* value^b^0.4050.806*p* value^c^0.0791.000*p* value^d^0.016\*0.729Lactobacilli countsT10 (0 ∼ 3)0 (0 ∼ 3)0.967T20 (0 ∼ 3)0 (0 ∼ 3)0.713T30 (0 ∼ 3)0 (0 ∼ 3)0.730*p* value^b^0.9800.658*p* value^c^0.1540.666*p* value^d^0.3170.902Buffer capacityT12 (1∼2, 2)2 (1∼2)0.971T22 (1∼2, 2)2 (1∼2)0.761T32 (1∼2, 2)2 (1∼2)0.599*p* value^b^0.5930.257*p* value^c^0.7960.366*p* value^d^0.7391.000Score of *Streptococcus mutans* counts: score = 0 for density less than or equal to 10^4^ CFU/ml, score = 1 for density between 10^4^ and 10^5^ CFU/ml, score = 2 for density between 10^5^ and 10^6^ CFU/ml, and score = 3 for density greater than 10^6^ CFU/ml. Score of lactobacilli counts: score = 0 for density equal to 10^3^ CFU/ml, score = 1 for density equal to 10^4^ CFU/ml, score = 2 for density equal to 10^5^ CFU/ml, and score = 3 for density equal to 10^6^ CFU/ml. Score of buffer capacity = 0 for low pH, score = 1 for intermediate pH, and score = 2 for high pH.T1: baseline (week 0), T2: the completion of medication (week 2), T3: 2 weeks after medication (week 4)\**p* \< 0.05, \*\**p* \< 0.01^a^Difference between probiotic and control group; to analyze the data, Mann--Whitney *U* test was used^b^Difference between T1 and T2; to analyze the data, Wilcoxon signed-rank test was used^c^Difference between T1 and T3; to analyze the data, Wilcoxon signed-rank test was used^d^Difference between T2 and T3; to analyze the data, Wilcoxon signed-rank test was used

Within the probiotic group, the *S. mutans* counts did not change during T1--T2. However, the reduction of *S. mutans* counts in the probiotic group was significantly different during T2--T3 (*p* = 0.016; Table [1](#Tab1){ref-type="table"}). The lactobacilli counts and buffer capacity of the probiotic group during T1--T2, T2--T3, and T1--T3 were not significantly different. The data was analyzed by Wilcoxon signed-rank test. (Table [1](#Tab1){ref-type="table"})

Within the control group, there were no significant differences in the *S. mutans* counts, lactobacilli counts and buffer capacity during T1--T2, T2--T3, and T1--T3. The data was analyzed by Wilcoxon signed-rank test. (Table [1](#Tab1){ref-type="table"})

The percentage of change in salivary *S. mutans* counts, lactobacilli counts, and buffer capacity was not significantly different in comparison with the probiotic group and control group during T1, T2, and T3. The data was analyzed by Fisher's exact test. Although we could not find significant difference, the level of *S. mutans* counts (\>10^5^ CFU/ml, score 2 and 3) showed a trend for reduction during T2--T3 and a slight increment during T1--T2 (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Percentage (95% confidence interval) of participants with high *Streptococcus mutans* counts (≥10^5^ CFU/ml, score 2 and 3) in probiotic (*n* = 42) and control (*n* = 36) groups at baseline (T1), the completion of medication (T2), and 2 weeks after medication (T3). (Fisher's exact test revealed *p* \> 0.05 (NS))

Discussion {#Sec9}
==========

There were no significant differences in the *S. mutans* counts, lactobacilli counts, and buffer capacity between the probiotic and control groups at T1, T2, and T3. There were several possible reasons suspected for the nonsignificant difference in *S. mutans* counts between the probiotic and control groups. First, there was the relatively small sample size in our study. Second, the subjects only took *L. paracasei* for 2 weeks in our study. In Nase's study, the intervention period of LGG was 7 months \[[@CR2]\]. The 2-week intervention period might be too short to express differences between two groups. Further *L. paracasei* GMNL-33 studies with extended intervention time and increased subjects will be encouraged. In addition, the concentration and vehicle type of *L. paracasei* would not be efficient enough for reducing *S. mutans* rapidly.

Within the probiotic group, an interesting probiotic effect was noticed. Between T1 and T2, no inhibitory effect against *S. mutans* was observed. However, a significant count reduction in the salivary *S. mutans* was detected between T2 and T3 (*p* = 0.016). It seemed likely that once this probiotic had colonized into the oral cavity, it could exert a beneficial effect which did not occur during a short-term intervention. Thus, a 2-week period of medication via oral administration route may be needed for *L. paracasei* GMNL-33 to be effective in the probiotic action.

In this present study, salivary count of *S. mutans* within the probiotic group was significantly reduced only between T2 and T3 (*p* = 0.016). The S. mutans lowering effect of probiotics was more pronounced in the posttreatment period (T2-T3) rather than the intervention period (T1-T2). The result was comparable to the studies of Ahola \[[@CR18]\] and Nikawa \[[@CR6]\]. Ahola et al. \[[@CR18]\] examined whether the short-term consumption of cheese containing LGG and *L. rhamnosus* LC 705 would diminish caries-associated salivary microbial counts in young adults. The results showed *S. mutans* counts were significantly reduced in the probiotic group, yet only during the posttreatment period. Nikawa et al. \[[@CR6]\] examined the effect of short-term yogurt consumption with *L. reuteri* on the oral carriage of *S. mutans*. The results suggested that *L. reuteri* in yogurt reduced the *S. mutans* counts for up to 2 weeks after discontinuing the consumption. Both short-term probiotic interventions seemed to enhance the inhibitory effect against *S. mutans* after the intervention. Although we used different species of probiotic bacteria, the posttreatment effect was similar. But the mechanism of this posttreatment effect was not clear. Further studies for investigating the mechanism of the posttreatment effects of the probiotics would be needed.

Daily consumption of lactobacilli might lead to a transient (albeit permanent) colonization of these bacteria \[[@CR19]\]. Busscher et al. \[[@CR20]\] and Petti et al. \[[@CR21]\] were unable to detect an oral colonization of lactobacilli after probiotic yogurt consumption. By contrast, Meurman et al. \[[@CR22]\] reported that LGG was detected for up to 2 weeks after discontinued consumption of probiotic yogurt. Another bacteriocin producer *S. salivarius* K12 was used as a probiotic targeting the oral cavity. Horz et al. \[[@CR23]\] monitored its dispersal and persistence in an oral environment by using real-time quantitative polymerase chain reaction. K12 could be detected at the mucosal membrane for 1 to 3 weeks yet with steadily decreasing tendency after 1 week. Thus probiotics may have the potential to control oral bacterial infections only when the uptake is repeated frequently.

We did not find statistically significant differences in the lactobacilli counts within and between probiotic versus control groups. However, there was a tendency for the probiotic intervention to increase the count levels of lactobacilli. Montalto investigated whether the oral administration of lactobacilli could change the salivary counts of these bacteria \[[@CR24]\]. It was found that the oral administration of probiotics significantly increased salivary counts of lactobacilli. In another study, the salivary lactobacilli counts also increased after intake of the probiotic-containing cheese \[[@CR18]\].

It should be noted that there were differences among various lactobacilli with regard to their abilities to cause dental caries. Some *Lactobacillus* species were identified in deep caries dentin and were related to dental caries progression. For example, *Lactobacillus acidophilus* and *Lactobacillus casei* Shirota might be strong agents in dental caries progression for their adhesive ability to dental surface \[[@CR25]\]. However, it had been suggested that not all strains of *Lactobacillus* spp. had a caries-inducing effect \[[@CR3]\]. In this study, the oral tablet contained *L. paracasei* extract that were not considered cariogenic. The elevation of count levels in lactobacilli could be reasonably considered as its well colonization in oral cavity under intervention instead of increasing caries risk \[[@CR24]\].

Along with *L. paracasei*, the well-documented *Lactobacillus* GG was not considered cariogenic and had been shown to exert inhibitory activity against *Streptococcus sobrinus* at pH values below 5 \[[@CR26]\]. The investigators also found that *Lactobacillus* GG did not ferment sucrose and thus did not promote caries. In addition, in vitro studies had shown that other lactobacilli, such as *Lactobacillus fermentum* and *L. salivarius*, had an inhibiting effect on the growth of *S. mutans* \[[@CR27]\] and *P. gingivalis* \[[@CR10]\]. All the lactobacilli except *Lactobacillus jensenii* produced bacteriocin against at least one of the indicator organisms. The ability of *Lactobacillus* spp. to protect their host against certain diseases by inhibiting the growth of potential pathogens was evident \[[@CR15]\].

Salivary buffer capacity was not changed in the current *L. paracasei* GMNL-33 study. It was not changed on other comparable probiotic studies either \[[@CR18]\].

In conclusion, the results of this study indicate that a 2-week period of medication at least may be needed for *L. paracasei* GMNL-33 via oral administration route to become effective in the probiotic action. And short-term probiotic intervention seemed to enhance its inhibitory effect against *S. mutans* after the intervention. Further studies for investigating the mechanism of the posttreatment effects of the probiotics would be needed.
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